Matches in Nanopublications for { ?s ?p ?o <http://purl.org/np/RAtSt1AfhVdbvp5RkBnMF3MQKhhuAANgdl51zijX_VouM#assertion>. }
Showing items 1 to 13 of
13
with 100 items per page.
- MONDO_0008114 type Disease assertion.
- DRUGBANK:DB01175 type Drug assertion.
- context type Cohort assertion.
- association type Statement assertion.
- context label "adults" assertion.
- association label "Escitalopram showed favorable pharmacokinetics and good tolerability. It is the most 5-HT-selective among SSRIs, with little or no affinity for other transmitter transporters or receptors [59]. Compared to other SSRIs, escitalopram may have weak or minimal interactions with the cytochrome P450 system [60, 61]. In a randomized, double-blind, placebo-controlled 24-week trial in OCD, escitalopram (20 mg/day) was associated with an increase in response rate compared to placebo after 12 weeks. Other placebo-controlled studies consistently showed escitalopram-related treatment response [25, 30]. 20 mg/day escitalopram has also been associated with better OCD symptom remission compared to 40 mg/day paroxetine or placebo at week 12 [30]. Three different escitalopram dosages (5, 10, and 20 mg/day) were compared with a fixed, 20 mg/day dose of paroxetine in a 12-week study, in which escitalopram showed both greater efficacy and better tolerability [62]." assertion.
- association object MONDO_0008114 assertion.
- association predicate treats assertion.
- association subject DRUGBANK:DB01175 assertion.
- association publications 30101713 assertion.
- association provided_by NeuroDKG assertion.
- association has_population_context context assertion.
- association relation OffLabelIndication assertion.